{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:32:33Z","timestamp":1777883553352,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>As the mandatory X-waiver requirements for prescribing buprenorphine have recently been lifted, general practitioners are being relied on to fill the treatment gap in prescribing medications for opioid use disorder (MOUD). However, insufficient clinician education remains a major barrier to prescribing MOUD in both inpatient and outpatient settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the impact of a new MOUD curriculum on internal medicine (IM) residents\u2019 attitudes, comfort, and knowledge of buprenorphine in the inpatient and outpatient settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All second-year IM residents (n\u2009=\u200946) participated in a 90-minute curricular session between July and October 2022 during scheduled mandatory didactic blocks. The curriculum was structured as a small group, case-based session focused on how to initiate sublingual buprenorphine (traditional and low-dose initiation). Residents completed identical and anonymous pre- and post-session surveys. A Wilcoxon signed rank test was used to analyze the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty-nine (84.4%) second-year IM residents participated in the evaluation. Residents reported increased importance of independently initiating buprenorphine for hospitalized patients with opioid withdrawal (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Residents were significantly more likely to endorse confidence in discussing MOUD with patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001), initiating buprenorphine in inpatient and outpatient settings (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001), and identifying patients who would benefit from low-dose buprenorphine initiation (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.002). There was a significant increase in the correct number of knowledge-based questions after the session (before\u2009=\u20091.55\/4 vs after\u2009=\u20093.33\/4;\n                      <jats:italic>P<\/jats:italic>\n                      value\u2009&lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A 90-minute buprenorphine training improved residents\u2019 attitudes toward, perceptions of competency, and knowledge of buprenorphine delivery to patients with OUD in the inpatient and outpatient setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342241261612","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T03:51:37Z","timestamp":1718769097000},"page":"231-237","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A Case-Based Curriculum on Buprenorphine for Treatment of Opioid Use Disorder Among Internal Medicine Residents"],"prefix":"10.1177","volume":"46","author":[{"given":"Minaliza","family":"Shahlapour","sequence":"first","affiliation":[{"name":"Department of Adult Medicine, East Boston Neighborhood Health Center, East Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0534-9888","authenticated-orcid":false,"given":"Alyssa F.","family":"Peterkin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston University Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6339-8675","authenticated-orcid":false,"given":"Sebastian","family":"Suarez","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine, Department of Medicine, University of Miami Miller School of Medicine. Miami, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Dydyk AM Jain NK Gupta M. Opioid Use Disorder. In: StatPearls [Internet]. StatPearls Publishing; 2022. Accessed September 16 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553166\/"},{"key":"e_1_3_3_3_2","volume-title":"Drug Overdose Deaths in the United States, 1999\u20132020","author":"Hedegaard H","year":"2021","unstructured":"Hedegaard H, Mini\u00f1o AM, Spencer MR, Warner M. Drug Overdose Deaths in the United States, 1999\u20132020. National Center for Health Statistics; 2021."},{"key":"e_1_3_3_4_2","unstructured":"Centers for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020\u2014but are still up 15%. 2022. Accessed November 18 2023. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2022\/202205.htm#print"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3549"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000377"},{"key":"e_1_3_3_7_2","unstructured":"Ali MM Creedon T Jacobus-Kantor L et al. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines. ASPE. Accessed April 3 2024. https:\/\/aspe.hhs.gov\/reports\/early-changes-after-2021-hhs-buprenorphine-practice-guidelines"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Madras BK Ahmad NJ Wen J Sharfstein J Prevention Treatment and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. National Academy of Medicine. 2020. Accessed February 15 2023. https:\/\/nam.edu\/improving-access-to-evidence-based-medical-treatment-for-opioid-use-disorder-strategies-to-address-key-barriers-within-the-treatment-system\/","DOI":"10.31478\/202004b"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109777"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.15766\/mep_2374-8265.11255"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000864"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000945"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001146"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001573"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2016.1187240"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0819-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.15766\/mep_2374-8265.11123"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13135"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15799"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S304566"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241261612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241261612","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241261612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:49:58Z","timestamp":1777600198000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241261612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/29767342241261612"],"URL":"https:\/\/doi.org\/10.1177\/29767342241261612","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]}}}